Andexanet alfa + 4F-PCC
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Anticoagulant-related Major Bleed
Conditions
Anticoagulant-related Major Bleed
Trial Timeline
Sep 15, 2022 → Dec 20, 2022
NCT ID
NCT05548777About Andexanet alfa + 4F-PCC
Andexanet alfa + 4F-PCC is a pre-clinical stage product being developed by AstraZeneca for Anticoagulant-related Major Bleed. The current trial status is completed. This product is registered under clinical trial identifier NCT05548777. Target conditions include Anticoagulant-related Major Bleed.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05548777 | Pre-clinical | Completed |